Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2002 Nov 16;325(7373):1139.
doi: 10.1136/bmj.325.7373.1139.

Bezafibrate in men with lower extremity arterial disease: randomised controlled trial

Tom Meade  1 , Riaz Zuhrie, Claire Cook, Jackie Cooper
Affiliations
Clinical Trial

Bezafibrate in men with lower extremity arterial disease: randomised controlled trial

Tom Meade et al. BMJ. .

Abstract

Objective: To assess the effect of bezafibrate on the risk of coronary heart disease and stroke in men with lower extremity arterial disease.

Design: Double blind placebo controlled randomised trial.

Setting: 85 general practices and nine hospital vascular clinics.

Participants: 1568 men, mean age 68.2 years (range 35 to 92) at recruitment.

Interventions: Bezafibrate 400 mg daily (783 men) or placebo (785 men).

Main outcome measures: Combination of coronary heart disease and of stroke. All coronary events, fatal and non-fatal coronary events separately, and strokes alone (secondary end points).

Results: Bezafibrate did not reduce the incidence of coronary heart disease and stroke. There were 150 and 160 events in the active and placebo groups respectively (relative risk 0.96, 95% confidence interval 0.76 to 1.21). There were 90 and 111 major coronary events in the active and placebo groups respectively (0.81, 0.60 to 1.08), of which 64 and 65 were fatal (0.95, 0.66 to 1.37) and 26 and 46 non-fatal (0.60, 0.36 to 0.99). Beneficial effects on non-fatal events were greatest in men aged <65 years at entry, in whom benefit was also seen for all coronary events (0.38, 0.20 to 0.72). There were no significant effects in older men. There were 60 strokes in those on active treatment and 49 in those on placebo (1.34, 0.80 to 2.01). There were 204 and 195 deaths from all causes in the two groups respectively (1.03, 0.83 to 1.26). Bezafibrate reduced the severity of intermittent claudication for up to three years.

Conclusions: Bezafibrate has no effect on the incidence of coronary heart disease and of stroke combined but may reduce the incidence of non-fatal coronary events, particularly in those aged <65 years at entry, in whom all coronary events may also be reduced.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Recruitment of men with lower extremity arterial disease
Figure 2
Figure 2
Withdrawals from and time on randomised treatment
Figure 3
Figure 3
Proportion of men who experienced end points during trial: totals at baseline were 783 in active treatment group and 785 in placebo group
See this image and copyright information in PMC

References

    1. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analysis of prospective studies. JAMA. 1998;279:1477–1482. - PubMed
    1. Resch KL, Ernst E, Matrai A, Paulsen HF. Fibrinogen and viscosity as risk factors for subsequent cardiovascular events in stroke survivors. Ann Intern Med. 1992;117:371–375. - PubMed
    1. Banerjee AK, Pearson J, Gilliland EL, Goss D, Lewis JD, Stirling Y, et al. A six year prospective study of fibrinogen and other risk factors associated with mortality in stable claudicants. Thromb Haemost. 1992;68:261–263. - PubMed
    1. Koster T, Rosendaal FR, Reitsma PH, van der Velden PA, Briet E, Vandenbroucke JP. Factor VII and fibrinogen levels as risk factors for venous thrombosis. Thromb Haemost. 1994;71:719–722. - PubMed
    1. Montalescot G, Ankri A, Vicaut E, Drobinnski G, Grosgogeat Y, Thomas D. Fibrinogen after coronary angioplasty as a risk factor for restenosis. Circulation. 1995;92:31–38. - PubMed

Publication types